Back to Search
Start Over
Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma
- Source :
- Expert Review of Hematology. 9:723-732
- Publication Year :
- 2016
- Publisher :
- Informa UK Limited, 2016.
-
Abstract
- A combination of granulocyte colony-stimulating factor (G-CSF) and chemotherapy or G-CSF alone are the most common mobilization regimens for autotransplantations. Plerixafor is used for mobilization of CD34(+) cells with G-CSF in non-Hodgkin lymphoma (NHL) and myeloma (MM) patients.The available phase II and III data on plerixafor has been reviewed. The efficacy of plerixafor in the mobilization of CD34(+) cells in predicted poor mobilizers as well as in patients who had failed a mobilization has been evaluated. The pre-emptive use of plerixafor as well as studies on cost-effectiveness are covered. Also effects in the composition of the collected grafts along with the data on long-term outcome of plerixafor-mobilized patients is discussed. Expert commentary: Plerixafor combined with G-CSF mobilizes CD34(+) cells more efficiently than G-CSF alone in patients with NHL or MM. In phase III studies, engraftment after high-dose therapy has been comparable to G-CSF mobilized patients. The pre-emptive use of plerixafor added to mobilization with chemotherapy plus G-CSF or with G-CSF alone has gained more popularity. This approach may be more cost-effective than the routine use of this drug. The changes observed in the composition of grafts after plerixafor injection may have implications for post-transplant events.
- Subjects :
- Oncology
Benzylamines
medicine.medical_specialty
Cost-Benefit Analysis
Premedication
medicine.medical_treatment
CD34
Antigens, CD34
Cyclams
Plerixafor Injection
03 medical and health sciences
Clinical Trials, Phase II as Topic
0302 clinical medicine
Heterocyclic Compounds
Internal medicine
medicine
Humans
Multiple myeloma
Chemotherapy
Mobilization
business.industry
Lymphoma, Non-Hodgkin
Plerixafor
Hematopoietic Stem Cell Transplantation
Hematology
Hematopoietic Stem Cells
medicine.disease
Hematopoietic Stem Cell Mobilization
Lymphoma
Treatment Outcome
Clinical Trials, Phase III as Topic
030220 oncology & carcinogenesis
Hodgkin lymphoma
Multiple Myeloma
business
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 17474094 and 17474086
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Expert Review of Hematology
- Accession number :
- edsair.doi.dedup.....fef0b475b31ca10eb17e07d0f18b71b6